Lyon ( France), May 28 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several up coming investor conferences in the United States and Europe in June 202 6 . To access the full release, please click on the PDF below....
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 Program launched in April to further reduce operating expenses Pfizer expected to file regulatory submissions for Lyme disease vaccine candidate Lyon (France), May 13, 2026 – Valneva SE...
Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update....
Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, announces the successful completion of an €84 million (including share issue premium) reserved offering subscribed by a limited number of investors (the “Reserved Offering”), including €37 million to be received upon...
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C....
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to...
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reduction in operating cash burn 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the...
Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will host a live webcast beginning at 3 p.m. CET/10 a.m. EDT to discuss the financial results and provide a business update....
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. To access the full release, please click on the PDF below....
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year Chief Executive...
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ ® , the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine....